Results 201 to 210 of about 104,817 (211)

Integrating machine-learning and nanotechnology to quantify pH-modulated oxaliplatin release. [PDF]

Sci Rep
Fathi-Karkan S, Rahdar A, Shirzad M.
europepmc   +1 more source

Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance. [PDF]

Front Cell Dev Biol
Han J, Liang W, Li K.
europepmc   +1 more source

Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study. [PDF]

J Clin Oncol
Conca V, Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Randon G, Lavacchi D, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Fazio R, Murgioni S, Borelli B, Buonadonna A, Germani MM, Formica V, Carullo M, Bordonaro R, Aprile G, Zaniboni A, Masi G, Boni L, Cremolini C.   +26 more
europepmc   +1 more source

Impact of Germline <i>BRCA</i> Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis. [PDF]

JCO Precis Oncol
Lee L, Tachibana Y, Matsuo S, Niina Y, Fujiyama T, Hisano T, Sugimoto R, Akashi T, Ogoshi K, Furukawa M.   +9 more
europepmc   +1 more source

Platinum-Based Cytostatics Used in Oncology with Respect to Environmental Fate and Innovative Removal Strategies of Their Metabolites. [PDF]

Molecules
Olchowski R, Morlo K, Dobrowolski R.
europepmc   +1 more source

Correction: Tian et al. Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1318. [PDF]

J Pers Med
Tian S, Su R, Wu K, Zhou X, Vadgama JV, Wu Y.   +5 more
europepmc   +1 more source

Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat. [PDF]

Oncol Rep
Röttgen H, Theurer L, Peccerella T, Sandu K, Weiss J, Burhenne J, Neoptolemos JP, Köberle B, Theile D.   +8 more
europepmc   +1 more source

Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells. [PDF]

Discov Oncol
Lu P, Zheng C, Zhang J, Zhu X, Chen X, Zhang J, Cao Y, Huang Z.   +7 more
europepmc   +1 more source

A case of descending colon cancer achieving a complete response with preoperative capecitabine plus oxaliplatin therapy following colorectal stenting. [PDF]

J Surg Case Rep
Mitsuhara C, Nishihara M, Ozawa N, Asano S.   +3 more
europepmc   +1 more source

Targeting the <i>ZMYM2-ANXA9</i> Axis: Organoid Models Illuminate a Novel Pathway to Overcome Oxaliplatin Resistance in Colorectal Cancer. [PDF]

Biomedicines
Zeng SJ, He K, Shi Z.
europepmc   +1 more source